US · SDGR
Schrödinger, Inc.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- New York City, NY 10036
- Website
- schrodinger.com
Price · as of 2025-12-31
$12.39
Market cap 888.4M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $34.23 | +176.27% |
| Intrinsic Value(DCF) | $5.72 | -53.83% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $43.32 | $44.23 | $1.81 | $0.00 | $0.00 |
| 2020 | $80.87 | $80.88 | $12.53 | $8.36 | $0.00 |
| 2021 | $28.80 | $116.32 | $6.38 | $0.78 | $0.00 |
| 2022 | $23.47 | $28.44 | $8.91 | $0.00 | $0.00 |
| 2023 | $27.16 | $42.92 | $3.08 | $10.41 | $15.36 |
| 2024 | $21.02 | $29.74 | $0.00 | $0.00 | $0.00 |
| 2025 | $12.15 | $34.23 | $1.40 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Schrödinger, Inc.'s (SDGR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $34.23
- Current price
- $12.39
- AI upside
- +176.27%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.72
-53.83% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SDGR | Schrödinger, Inc. | $12.39 | 888.4M | +176% | -54% | — | — | -8.64 | 2.45 | 3.49 | -6.29 | — | 2.48 | 55.74% | -65.23% | -40.36% | -26.29% | -125.97% | -13.33% | 0.30 | — | 2.75 | 2.53 | 1.26 | -4514.00% | 2329.00% | -10756.00% | 1.40% | 0.07 | 9.40% | 0.00% | 0.00% | 10.29% | -3.63 | 48.66 | 2.37 | 0.41 |
| ABCL | AbCellera Biologics Inc. | $3.61 | 1.08B | +1,038% | -58% | -83% | — | -7.79 | 1.18 | 15.19 | -5.71 | — | 1.30 | 100.00% | -288.98% | -194.88% | -14.47% | -29.60% | -10.78% | 0.29 | — | 11.32 | 9.21 | -0.98 | -1091.00% | 16056.00% | -689.00% | -15.25% | -2.04 | -28.78% | 0.00% | 0.00% | 0.00% | -4.09 | -5.10 | 11.82 | 2.19 |
| AZTA | Azenta, Inc. | $26.98 | 1.24B | +62% | -42% | -40% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| EVO | Evotec SE | $3.40 | 1.21B | +721% | -44% | — | — | -5.60 | 1.15 | 1.38 | -14.20 | -3.91 | 1.71 | 14.41% | -17.88% | -24.60% | -18.92% | -12.23% | -9.42% | 0.47 | -12.18 | 1.98 | 1.79 | -1.70 | 14348.00% | 199.00% | -3650.00% | -10.38% | 0.05 | -9.79% | 0.00% | 0.00% | 15.22% | -8.04 | -10.05 | 1.44 | 0.58 |
| IMNM | Immunome, Inc. | $21.86 | 2B | +132% | -83% | — | +492% | -1.87 | 3.02 | 60.58 | -2.21 | — | 3.02 | 100.00% | -3382.37% | -3240.38% | -194.63% | 1276.40% | -150.71% | 0.03 | — | 4.08 | 4.00 | 0.92 | -706.00% | -3550.00% | 185621.00% | -30.00% | -2.04 | 685.79% | 0.00% | 0.00% | 7.58% | -1.10 | -2.04 | 37.08 | -0.77 |
| OMCL | Omnicell, Inc. | $41.10 | 1.89B | +33% | -57% | -73% | -98% | 924.00 | 1.54 | 1.60 | 19.91 | — | 5.86 | 42.49% | 0.44% | 0.17% | 0.17% | 0.17% | 0.10% | 0.18 | 0.84 | 1.43 | 0.87 | 0.21 | -8359.00% | 653.00% | -4256.00% | 4.58% | 0.27 | 6.96% | 0.00% | 0.00% | 4.09% | 371.46 | 22.06 | 1.62 | 2.26 |
| OMDA | Omada Health | $12.28 | 711.11M | — | — | — | — | — | — | — | — | — | — | 60.59% | -25.71% | -27.76% | -57.64% | -270.44% | -28.92% | 0.47 | -9.69 | 2.10 | 1.86 | 1.22 | -2975.00% | 3829.00% | -2776.00% | — | -0.63 | -235.67% | — | 0.00% | — | — | — | — | — |
| PGNY | Progyny, Inc. | $17.69 | 1.53B | +175% | +6% | -48% | -30% | 25.63 | 2.91 | 1.16 | 12.09 | 182.64 | 3.06 | 23.63% | 6.62% | 4.54% | 12.48% | 23.59% | 8.67% | 0.05 | — | 2.73 | 2.62 | -0.88 | 1404.00% | 1040.00% | 1041.00% | 12.78% | 1.04 | 86.52% | 0.00% | 0.00% | 5.44% | 14.24 | 6.33 | 0.94 | 6.66 |
| PHR | Phreesia, Inc. | $12.33 | 743.34M | +427% | +131% | — | — | -23.67 | 5.23 | 3.30 | -51.58 | — | 12.82 | 67.86% | -13.84% | -13.94% | -22.67% | -31.04% | -15.43% | 0.07 | -24.75 | 1.78 | 1.38 | 2.60 | -5936.00% | 1783.00% | -11443.00% | 0.60% | 0.28 | 4.43% | 0.00% | 0.00% | 0.00% | -22.71 | 159.09 | 3.14 | 4.70 |
| TDOC | Teladoc Health, Inc. | $5.26 | 933.51M | +398% | -42% | -89% | — | -4.54 | 0.66 | 0.36 | 7.86 | — | -4.67 | 69.50% | -10.39% | -7.92% | -13.93% | -13.11% | -6.28% | 0.74 | -13.34 | 2.77 | 2.41 | 1.68 | -8058.00% | -154.00% | 91.00% | 31.39% | 0.73 | 16.74% | 0.00% | 0.00% | 4.21% | -4.40 | 4.05 | 0.46 | -6.80 |
| TXG | 10x Genomics, Inc. | $23.05 | 2.94B | +141% | -55% | -80% | — | -66.29 | 3.63 | 4.49 | -22.74 | — | 3.96 | 69.05% | -17.25% | -6.77% | -5.78% | -26.72% | -4.44% | 0.20 | — | 4.46 | 3.95 | 2.85 | -7697.00% | 525.00% | -237116.00% | 4.51% | 0.89 | 31.35% | 0.00% | 0.00% | 1.90% | -22.74 | 19.38 | 3.92 | 5.92 |
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
- CEO
- Ramy Farid
- Employees
- 891
- Beta
- 1.55
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.72 ÷ $12.39) − 1 = -53.83% (DCF, example).